Strain-Independent Therapeutic Antibodies for Influenza

描述(由申请人提供)：格子生物科学公司的CellSpot“鉴定具有高度特异性和亲和力的稀有人类抗体的技术使我们能够发现高效的针对呼吸道合胞病毒和巨细胞病毒的株无关抗体。我们现在已经应用CellSpot分离出两种对第一和第二组甲型流感病毒株具有广泛反应性的天然人抗体。这两种抗体现在都被证明在体内有效。此外，我们还分离出了一种具有体外抗B型流感活性的人抗体。我们建议将这些候选治疗方案推进到IND阶段，包括进一步的体外中和研究和进一步的中和研究。 体内、制造、毒性和PK研究。由此产生的临床候选人预计将 对所有目前流行的毒株提供有效的感染后抗病毒活性，并对任何新出现的大流行毒株进行有效预防。

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.